Get the Stockscreener App
0.6998
0.11%
0.0008
Context Therapeutics Inc stock is traded at $0.6998, with a volume of 64,958.
It is up +0.11% in the last 24 hours and up +8.18% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.699
Open:
$0.7046
24h Volume:
64,958
Relative Volume:
0.29
Market Cap:
$62.77M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.769
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
-4.14%
1M Performance:
+8.18%
6M Performance:
-19.86%
1Y Performance:
-70.09%
1-Day Range:
$0.695
$0.72
1-Week Range:
$0.6752
$0.7667
52-Week Range:
$0.49
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.6998 | 62.79M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.64 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.36 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.31 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.12 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results - GlobeNewswire
Context Therapeutics Q2 Earnings: Strong $83.5M Cash Position Funds Two Key Cancer Drug Trials - Stock Titan
Best data tools to analyze Context Therapeutics Inc. stockBuy and Exit Strategy Based on Momentum - Newser
How Context Therapeutics Inc. stock performs during market volatilityFree AI-Powered Trade Planning with Indicators - Newser
Detecting support and resistance levels for Context Therapeutics Inc.Free Growth Based Investment Plan Guidance - Newser
What makes Context Therapeutics Inc. stock price move sharplyFree Real-Time Analysis With Entry Targets - Newser
Context Therapeutics Inc. Stock Support and Resistance Levels You Should KnowStock Price Prediction Using AI Tools - Newser
How sentiment analysis helps forecast Context Therapeutics Inc.Free Market Momentum and Signal Alerts - Newser
What technical models suggest about Context Therapeutics Inc.’s comebackShort-Term AI-Based Stock Price Forecast - Newser
Custom strategy builders for tracking Context Therapeutics Inc.Safe and Scalable Return Strategy Blueprint - Newser
Analyzing net buyer seller activity in Context Therapeutics Inc.AI Generated Momentum Stock Forecast Guide - Newser
Is Context Therapeutics Inc. a good long term investmentUnlock market-leading stock analysis - Jammu Links News
Why Context Therapeutics Inc. stock attracts strong analyst attentionWeekly Stock Market Strategy Summary - Newser
When is Context Therapeutics Inc. stock expected to show significant growthNavigate market shifts with confidence - Jammu Links News
How does Context Therapeutics Inc. compare to its industry peersUnlock powerful trading signals and alerts - Jammu Links News
Is it the right time to buy Context Therapeutics Inc. stockCapitalize on momentum-driven investment opportunities - Jammu Links News
What are the latest earnings results for Context Therapeutics Inc.Outstanding investment returns - Jammu Links News
What is the risk reward ratio of investing in Context Therapeutics Inc. stockRapid wealth multiplication - Jammu Links News
How strong is Context Therapeutics Inc. company’s balance sheetIdentify breakout stocks before they peak - Jammu Links News
What is the dividend policy of Context Therapeutics Inc. stockRapid wealth accumulation - Jammu Links News
What institutional investors are buying Context Therapeutics Inc. stockMaximize gains with expert analysis - Jammu Links News
How many analysts rate Context Therapeutics Inc. as a “Buy”High-performance stocks for savvy investors - Jammu Links News
Wyckoff Accumulation Phase Possible in Context Therapeutics Inc.Daily Momentum Screener With Alerts Launched - metal.it
What analysts say about Context Therapeutics Inc. stock outlookImmediate Entry Point Prediction Strategy - Newser
Full technical analysis of Context Therapeutics Inc. stockFree Community Strategy With High Win Rate - Newser
How Resilient Is Context Therapeutics Inc. Stock During Economic DownturnsHigh Conviction Stock Long-Term Summary - Newser
Published on: 2025-07-30 09:29:19 - beatles.ru
Published on: 2025-07-30 01:03:52 - Newser
Context Therapeutics Inc. Breakout Confirmed by Volume MetricsTriple Digit Return Stock Predictions Released - metal.it
Context Therapeutics Inc. Rebound Backed by Sentiment ShiftAlpha Focused Technical Trade Signals Gain Attention - metal.it
Context Therapeutics Inc. stock prediction for this weekReliable Setup Screener with Low Risk - Newser
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):